SCHEMBL25054067

SCHEMBL25054067

C/C=C/C=C/C(=O)Nc1ccccc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 8/20 0.59
▸ TRPM8 Q7Z2W7 6/20 0.59
▸ TRPM2 O94759 2/20 0.57
▸ LTB4R Q15722 1/20 0.57
▸ KMT2A Q03164 5/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ MEN1 O00255 4/20 0.56
▸ NPC1 O15118 3/20 0.56
▸ RAB9A P51151 3/20 0.56
▸ MAPT P10636 2/20 0.56
▸ KDM4E B2RXH2 3/20 0.55
▸ APEX1 P27695 2/20 0.55
▸ RECQL P46063 2/20 0.55
▸ POLB P06746 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ MASP2 O00187 1/20 0.53
▸ HTT P42858 2/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ HPGD P15428 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10199005 0.89 TRPM2 (0.61) TRPA1TRPM8TRPM2LTB4RKMT2A
SCHEMBL14206787 0.89 TRPM2 (0.61) TRPA1TRPM8TRPM2LTB4RKMT2A
SCHEMBL10199018 0.80 ALDH1A1 (0.76) TRPA1TRPM8TRPM2LTB4RKMT2A
SCHEMBL10936745 0.80 ALDH1A1 (0.76) TRPA1TRPM8TRPM2LTB4RKMT2A
SCHEMBL294402 0.78 TRPM2 (0.83) TRPA1TRPM8TRPM2LTB4RKMT2A
SCHEMBL294403 0.78 TRPM2 (0.83) TRPA1TRPM8TRPM2LTB4RKMT2A
SCHEMBL20342066 0.76 ALDH1A1 (0.50) TRPA1TRPM8TRPM2LTB4RKMT2A
SCHEMBL8635718 0.76 TRPA1 (0.78) TRPA1TRPM8TRPM2LTB4RKMT2A
SCHEMBL8635715 0.76 TRPA1 (0.78) TRPA1TRPM8TRPM2LTB4RKMT2A
SCHEMBL8844920 0.76 LMNA (0.64) TRPA1TRPM8TRPM2LTB4RKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2023-05-11 — — US disclosed
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2023-05-11 — — US disclosed
US-11584714-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584714-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 TRPA1 4838/4885TRPM8 3570/4885TRPM2 2624/4885
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 TRPA1 4838/4885TRPM8 3570/4885TRPM2 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback